A phase I/II study of cabazitaxel (Cbz) combined with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed after docetaxel (D) chemotherapy: Preliminary results.
Christophe Massard
Consultant or Advisory Role - Janssen Pharmaceutical ; Sanofi
Carmel Pezaro
Employment or Leadership Position - Institute of Cancer Research, ICR
Honoraria - Sanofi
Other Remuneration - Janssen Pharmaceutical
Dmitri Bobilev
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Aurelius Gabriel Omlin
Employment or Leadership Position - Institute of Cancer Research, ICR
Diletta Bianchini
No relevant relationships to disclose
David Lorente Estelles
Employment or Leadership Position - Institute of Cancer Research, ICR
Laurence Albiges
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Yohann Loriot
Honoraria - Sanofi
Research Funding - Sanofi
Andrea Varga
No relevant relationships to disclose
Thi Xuan Quyen Nguyen
Employment or Leadership Position - Sanofi
Karim Fizazi
Consultant or Advisory Role - Janssen Pharmaceutical ; Sanofi
Johann Sebastian De Bono
Employment or Leadership Position - Institute of Cancer Research, ICR
Consultant or Advisory Role - Sanofi
Honoraria - Astellas Pharma; Johnson & Johnson; Sanofi
Research Funding - Sanofi